Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXSMNYSE:BHCNASDAQ:JAZZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$101.65+1.0%$106.72$72.21▼$139.13$4.96B0.48677,733 shs638,409 shsBHCBausch Health Cos$6.11-1.1%$5.02$3.96▼$9.85$2.29B0.282.62 million shs2.30 million shsJAZZJazz Pharmaceuticals$106.76-0.7%$108.24$95.49▼$148.06$6.51B0.33826,185 shs509,761 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics0.00%-3.28%-4.17%-22.05%+31.81%BHCBausch Health Cos0.00%+2.58%+38.50%-15.07%-9.26%JAZZJazz Pharmaceuticals0.00%-0.91%-0.52%-24.30%-0.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXSMAxsome Therapeutics4.7172 of 5 stars4.52.00.04.52.04.20.6BHCBausch Health Cos3.6843 of 5 stars1.92.00.04.03.93.30.6JAZZJazz Pharmaceuticals4.9127 of 5 stars4.52.00.04.02.93.32.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXSMAxsome Therapeutics 3.06Buy$172.3369.54% UpsideBHCBausch Health Cos 1.86Reduce$7.4221.39% UpsideJAZZJazz Pharmaceuticals 2.92Moderate Buy$184.0072.35% UpsideCurrent Analyst Ratings BreakdownLatest AXSM, JAZZ, and BHC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025AXSMAxsome TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$193.00 ➝ $186.006/11/2025JAZZJazz PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$202.006/10/2025AXSMAxsome TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$180.006/9/2025AXSMAxsome TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$153.00 ➝ $150.006/3/2025AXSMAxsome TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$185.006/3/2025JAZZJazz PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$202.005/22/2025AXSMAxsome TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$180.00 ➝ $180.005/14/2025AXSMAxsome TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/7/2025AXSMAxsome TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$200.00 ➝ $180.005/7/2025JAZZJazz PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$182.00 ➝ $172.005/7/2025JAZZJazz PharmaceuticalsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$167.00 ➝ $155.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXSMAxsome Therapeutics$385.69M12.98N/AN/A$1.18 per share86.14BHCBausch Health Cos$9.63B0.23$7.64 per share0.80($0.89) per share-6.87JAZZJazz Pharmaceuticals$4.07B1.59$30.16 per share3.54$67.72 per share1.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXSMAxsome Therapeutics-$287.22M-$5.77N/A36.05N/A-64.39%-272.80%-36.69%8/4/2025 (Estimated)BHCBausch Health Cos-$46M-$0.11N/A1.31N/A-0.41%-540.45%5.26%7/30/2025 (Estimated)JAZZJazz Pharmaceuticals$560.12M$7.5014.235.714.6411.86%26.62%9.14%7/30/2025 (Estimated)Latest AXSM, JAZZ, and BHC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025JAZZJazz Pharmaceuticals$4.65$1.68-$2.97-$1.52$984.16 million$897.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ABHCBausch Health CosN/AN/AN/AN/AN/AJAZZJazz PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXSMAxsome Therapeutics3.482.031.96BHCBausch Health CosN/A1.350.97JAZZJazz Pharmaceuticals1.283.382.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXSMAxsome Therapeutics81.49%BHCBausch Health Cos78.65%JAZZJazz Pharmaceuticals89.14%Insider OwnershipCompanyInsider OwnershipAXSMAxsome Therapeutics22.40%BHCBausch Health Cos8.12%JAZZJazz Pharmaceuticals4.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXSMAxsome Therapeutics38049.24 million38.21 millionOptionableBHCBausch Health Cos20,700370.08 million340.03 millionOptionableJAZZJazz Pharmaceuticals2,80060.51 million57.91 millionOptionableAXSM, JAZZ, and BHC HeadlinesRecent News About These CompaniesEU reviews risk of abuse in some treatments for alcohol dependency (June 20)June 23 at 5:20 PM | msn.comEU reviews risk of abuse in some treatments for alcohol dependencyJune 20 at 5:51 PM | msn.comBoston Trust Walden Corp Acquires New Holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)June 20 at 5:02 AM | marketbeat.comFriedenthal Financial Invests $858,000 in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)June 19, 2025 | marketbeat.comCWA Asset Management Group LLC Sells 2,963 Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)June 19, 2025 | marketbeat.comFifth Third Bancorp Has $449,000 Holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)June 18, 2025 | marketbeat.com15,296 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Acquired by Ritholtz Wealth ManagementJune 17, 2025 | marketbeat.comSG Americas Securities LLC Purchases New Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)June 17, 2025 | marketbeat.com5,050 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Purchased by New England Research & Management Inc.June 14, 2025 | marketbeat.comNew Century Financial Group LLC Invests $388,000 in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)June 14, 2025 | marketbeat.comStifel Nicolaus Remains a Buy on Jazz Pharmaceuticals (JAZZ)June 13, 2025 | theglobeandmail.comRaymond James Keeps Their Hold Rating on Jazz Pharmaceuticals (JAZZ)June 13, 2025 | theglobeandmail.comCX Institutional Purchases Shares of 34,768 Jazz Pharmaceuticals plc (NASDAQ:JAZZ)June 12, 2025 | marketbeat.comMerit Financial Group LLC Purchases New Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)June 12, 2025 | marketbeat.comJazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav®June 11, 2025 | msn.comFDA Grants Priority Review to Jazz Pharmaceuticals’ Zepzelca in Combination with Tecentriq for Extensive-Stage Small Cell Lung CancerJune 11, 2025 | pharmexec.comJazz Pharmaceuticals' (JAZZ) "Buy" Rating Reaffirmed at Needham & Company LLCJune 11, 2025 | marketbeat.comUSA Financial Formulas Makes New Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)June 11, 2025 | marketbeat.comFirst Citizens Bank & Trust Co. Purchases New Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)June 11, 2025 | marketbeat.comHER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020-2034) | DelveInsightJune 10, 2025 | finance.yahoo.comZepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung CancerJune 10, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAXSM, JAZZ, and BHC Company DescriptionsAxsome Therapeutics NASDAQ:AXSM$101.65 +0.96 (+0.95%) Closing price 04:00 PM EasternExtended Trading$103.65 +2.00 (+1.97%) As of 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Bausch Health Cos NYSE:BHC$6.11 -0.07 (-1.13%) Closing price 03:59 PM EasternExtended Trading$6.14 +0.03 (+0.51%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Jazz Pharmaceuticals NASDAQ:JAZZ$106.76 -0.75 (-0.70%) Closing price 04:00 PM EasternExtended Trading$105.98 -0.79 (-0.74%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
